275 related articles for article (PubMed ID: 19580463)
1. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs.
Allen MR; Kubek DJ; Burr DB
J Bone Miner Res; 2010 Jan; 25(1):98-105. PubMed ID: 19580463
[TBL] [Abstract][Full Text] [Related]
2. Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible.
Kubek DJ; Burr DB; Allen MR
Orthod Craniofac Res; 2010 Nov; 13(4):214-22. PubMed ID: 21040464
[TBL] [Abstract][Full Text] [Related]
3. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
4. Effects of short-term zoledronic acid treatment on bone remodeling and healing at surgical sites in the maxilla and mandible of aged dogs.
Huja SS; Mason A; Fenell CE; Mo X; Hueni S; D'Atri AM; Fernandez SA
J Oral Maxillofac Surg; 2011 Feb; 69(2):418-27. PubMed ID: 21122971
[TBL] [Abstract][Full Text] [Related]
5. Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness.
Luo TD; Allen MR
Bone; 2013 Sep; 56(1):199-203. PubMed ID: 23774445
[TBL] [Abstract][Full Text] [Related]
6. A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration.
Carvas JS; Pereira RM; Caparbo VF; Fuller P; Silveira CA; Lima LA; Bonfa E; Mello SB
Osteoporos Int; 2010 Oct; 21(10):1723-9. PubMed ID: 19997905
[TBL] [Abstract][Full Text] [Related]
7. Mandibular necrosis in beagle dogs treated with bisphosphonates.
Burr DB; Allen MR
Orthod Craniofac Res; 2009 Aug; 12(3):221-8. PubMed ID: 19627524
[TBL] [Abstract][Full Text] [Related]
8. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats.
Chen B; Li Y; Yang X; Xu H; Xie D
Osteoporos Int; 2013 Jul; 24(7):2115-21. PubMed ID: 23389695
[TBL] [Abstract][Full Text] [Related]
10. Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone.
Allen MR; Chu TM; Ruggiero SL
J Oral Maxillofac Surg; 2013 Jun; 71(6):1017-26. PubMed ID: 23375897
[TBL] [Abstract][Full Text] [Related]
11. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease.
Allen MR; Chen NX; Gattone VH; Chen X; Carr AJ; LeBlanc P; Brown D; Moe SM
Osteoporos Int; 2013 Apr; 24(4):1471-81. PubMed ID: 22907737
[TBL] [Abstract][Full Text] [Related]
12. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment.
Allen MR; Reinwald S; Burr DB
Calcif Tissue Int; 2008 May; 82(5):354-60. PubMed ID: 18463913
[TBL] [Abstract][Full Text] [Related]
13. Oncologic doses of zoledronic acid induce site specific suppression of bone modelling in rice rats.
Exposto CR; Oz U; Callard JS; Allen MJ; Khurana H; Atri A; Mo X; Fernandez SA; Tatakis DN; Edmonds K; Westgate PM; Huja SS
Orthod Craniofac Res; 2017 Jun; 20 Suppl 1():83-88. PubMed ID: 28643933
[TBL] [Abstract][Full Text] [Related]
14. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment.
Allen MR; Burr DB
J Oral Maxillofac Surg; 2008 May; 66(5):987-94. PubMed ID: 18423290
[TBL] [Abstract][Full Text] [Related]
15. Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing.
Swallow EA; Aref MW; Metzger CE; Sacks S; Lehmkuhler DR; Chen N; Hammond MA; Territo PR; Nickolas TL; Moe SM; Allen MR
Bone; 2019 Oct; 127():419-426. PubMed ID: 31299384
[TBL] [Abstract][Full Text] [Related]
16. Early inhibitory effects of zoledronic acid in tooth extraction sockets in dogs are negated by recombinant human bone morphogenetic protein.
Gerard DA; Carlson ER; Gotcher JE; Pickett DO
J Oral Maxillofac Surg; 2014 Jan; 72(1):61-6. PubMed ID: 23891015
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
[TBL] [Abstract][Full Text] [Related]
20. Additive effects of zoledronic acid and propranolol on bone density and biochemical markers of bone turnover in osteopenic ovariectomized rats.
Khajuria DK; Razdan R; Mahapatra DR
Rev Bras Reumatol; 2015; 55(2):103-12. PubMed ID: 25582996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
